As I prepared to go to the annual tuberculosis (TB) Union meeting in October, friends and colleagues mentioned that they had heard the good news about TB, that incidence is falling. And I would respond that only 0.5% of people who have multi drug resistant TB (MDR-TB) are being treated. I went to Lille, France with my colleagues to roll up our sleeves and do something about this.
Our work over the last six months with Eli Lilly and Company was announced last week: a five-year, $30M commitment
to the third phase of the Lilly MDR-TB Partnership
, focusing on second line drug supply and access, and health care provider training. With so many problems in MDR-TB, it was not easy to choose a focus. Lilly takes an approach throughout its programs to create long term impact through its activities under the framework of Research, Report and Advocate – you can read more about this work from our client, Tracy Sims in a recent blog post